Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1066
Title: Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea
Authors: Forsyth, Cecily J ;Douglas, G.;Harrison, C.N.;Bennett, M.;Stevenson, W.S.;Hounsell, J.;Ratnasingam, S.;Ritchie, D.;Ross, D.M.;Grigg, A.
Affliation: Central Coast Local Health District
Gosford Hospital
Issue Date: Jan-2017
Source: 58(1):89-95
Journal title: Leukemia & lymphoma
Department: Haematology
Abstract: Hydroxyurea (Hu) is widely used as first-line cytoreductive therapy for patients with high-risk Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPN), but a small proportion of patients have refractory disease or experience adverse effects. Studies have demonstrated busulfan (Bu) to be an active first-line agent, but data on its role as second-line or later therapy are minimal. To evaluate its efficacy and safety in this context, we undertook a multicenter audit of Ph-neg MPN patients who had received Bu as therapy for Hu intolerance or failure. Of 51 patients identified, 38 (75%) achieved either complete or partial hematological response following at least one Bu cycle. Bu was generally well tolerated, with only 21/135 (15%) cycles complicated by adverse effects, predominantly cytopenia; only 6% of cycles were ceased due to treatment complications. Bu is an effective and well-tolerated agent in patients with Ph-neg MPN in the setting of Hu intolerance or unresponsiveness.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1066
DOI: 10.1080/10428194.2016.1187269
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/27454522
ISSN: 1026-8022
Publicaton type: Journal Article
Keywords: Drug Therapy
Appears in Collections:Haematology

Show full item record

Page view(s)

40
checked on Jan 30, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.